ASCO 2026: AI Challenges a Breast Cancer Standard

New data suggest AI-based analysis of pathology slides may provide additional prognostic information, particularly for patients in the intermediate-risk category

By
Jessica Allerton
June 4, 2026
3 min

The Pathologist

At a Glance

Category	Detail
Condition	Early-stage breast cancer
Key Mechanisms	Multimodal artificial intelligence histopathology-based tool versus the 21-gene recurrence score
Target Population	Patients with ER positive, HER2 negative early-stage breast cancer
Care Setting	Oncology

Key Highlights

Artera breast model includes digital pathology and clinical variables.
FDA-cleared and CE-marked risk stratification tool.
Study involved over 300 patients with early-stage breast cancer.
Artera AI tool shows additional prognostic value over the 21-gene recurrence score.
Significant differences in 10-year distant metastasis rates based on score concordance.

Guideline-Based Recommendations

Diagnosis

Utilize the Artera AI tool for risk stratification in early-stage breast cancer.

Management

Consider the prognostic information from the Artera AI tool in treatment decisions.

Monitoring & Follow-up

Monitor patients with discordant scores for higher distant metastasis rates.

Risks

Higher 10-year distant metastasis rates observed in patients with discordant scores.

Patient & Prescribing Data

Patients with ER positive, HER2 negative early-stage breast cancer.

Majority of patients in the study did not receive chemotherapy.

Clinical Best Practices

Incorporate multimodal AI tools in clinical practice for better prognostic assessment.
Evaluate both Artera scores and 21-gene recurrence scores for comprehensive risk stratification.